DSP Mutual Fund · Direct Growth · SEBI Category: Equity
DSP Healthcare Fund invests in a comprehensive range of healthcare sector companies — pharmaceutical manufacturers, API suppliers, contract research and manufacturing organisations (CROs/CMOs), hospitals, diagnostic chains and medical device makers. DSP MF's systematic research framework is applied to healthcare sector investing — evaluating companies on the quality of their regulatory track record, management credibility, revenue diversification and long-term competitive position.
The fund benefits from DSP MF's disciplined investment process — companies are evaluated systematically on both financial quality and regulatory quality. This is particularly important in the pharma sector where regulatory compliance history is as important as financial metrics. The fund's Nifty Healthcare benchmark — broader than the Nifty Pharma index — reflects its comprehensive healthcare mandate.
Chirag Dagli is Fund Manager at DSP Mutual Fund and manages DSP Healthcare Fund. He brings deep analytical expertise in the pharmaceutical and healthcare sector — covering the full value chain from API manufacturers through formulation companies, contract research organisations (CROs), hospitals, diagnostics and medical devices. His research-driven approach identifies opportunities across the healthcare ecosystem based on business quality and valuation.
For current co-manager details and full biography, refer to the latest DSP Mutual Fund factsheet on AMFI or the AMC website.
Informational points to help you form your own view — not judgements or recommendations.
Live data. Current fund highlighted. Click any fund name for full analysis.
| Fund | NAV | AAUM | 1Y Return | 3Y CAGR | 5Y CAGR | Sharpe (3Y) |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund | ₹596.02 | ₹7.9K Cr Jan–Mar 2026 | +5.9% | +22.5% p.a. | +13.4% p.a. | 1.37 |
| SBI Healthcare Opportunities Fund | ₹532.86 | ₹3.8K Cr Jan–Mar 2026 | +10.5% | +25.5% p.a. | +16.2% p.a. | 1.61 |
| DSP Healthcare Fund ▲ | ₹46.10 | ₹3.0K Cr Jan–Mar 2026 | +8.8% | +22.9% p.a. | +15.4% p.a. | 1.62 |
| Mirae Asset Healthcare Fund | ₹47.02 | ₹2.7K Cr Jan–Mar 2026 | +13.9% | +25.8% p.a. | +15.6% p.a. | 1.45 |
| HDFC Pharma and Healthcare Fund | ₹20.01 | ₹1.9K Cr Jan–Mar 2026 | +19.9% | — | — | — |
Calculated from 1,826 daily NAV records in RightAdvise DB. Last calculated: Jun 2026.
1M / 3M / 6M / 1Y — simple point-to-point return · 3Y / 5Y / 10Y — CAGR (compounded annual growth rate)
Based on all rolling windows in full NAV history. Dates show the start and end of each period.
Jan 1 to Dec 31 each year. Simple point-to-point — not CAGR.
Rolling returns show performance across every possible investment start date — not one cherry-picked number. Learn more →
How much the fund fell from its peak NAV — what investors actually experience during crashes. Calculated from full NAV history.
Calculated from actual NAV data. "Pre-inception" means the fund didn't exist during that period.
Calculated from 3 years of daily NAV — industry standard. Risk-free rate: 6.5% p.a. Last updated: Jun 2026. What do these mean? →
Our portfolio holdings page shows every stock the fund owns, sector allocation, and month-over-month changes — from official AMC disclosures.
See how DSP Healthcare Fund ranks against other Equity funds on returns, drawdown, Sharpe ratio and AAUM — side by side.
New fund analysis, articles and market insights — no spam, no selling. Unsubscribe anytime.
Found this useful? Share it
Found an error? Have a suggestion? We read every response.